

Experimental anti-inflammatory drug Semapimod inhibits Toll-like receptor signaling by targeting the TLR chaperone gp96

Supporting information





Fig. S1. Semapimod desensitizes responses to CpG DNA. (A) Phospho-p38/p38 ratio as function of CpG DNA concentration in the presence of 0, 1, or 10 μ M Semapimod. (B) Phospho-p38/p38 ratio following treatment with 5, 20, or 100 μ g/ml CpG DNA as function of Semapimod concentration. Standard deviations of individual values are \pm 20% or less